Skip to content

Low-osmolar Water Soluble Contrast Agent in Management of Adhesive Small Bowel Obstruction

Randomized Controlled Trial of Low-osmolar Water Soluble Contrast Agent in Management of Adhesive Small Bowel Obstruction

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06140173
Enrollment
66
Registered
2023-11-18
Start date
2024-06-30
Completion date
2025-07-31
Last updated
2024-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Bowel Adhesion, Small Bowel Obstruction

Brief summary

Adhesive small bowel obstruction (ASBO) is a condition that is commonly found in patients with history of abdominal surgery. The management for such condition can be controversial. In terms of conservative treatment, recent studies have shown conflicting outcomes on whether water soluble contrast would provide benefit in reducing number of patients needed for surgery. In addition, there are a limited number of literature that investigates the role of low-osmolar contrast in reducing operative need in patients diagnosed with ASBO. The objective of this study is to compare the operative rate of patient diagnosed with ASBO between patients who were treated with low osmolar water soluble contrast (Iohexol) and patients who were treated traditionally.

Detailed description

This study is a randomized, controlled and double-blinded study, where participants who were diagnosed with ASBO will be randomly allocated into two groups: (i) A contrast group (CG): Patients will be treated conservatively and received Omnipaque (Iohexol) via nasogastric tube (ii) A traditional group (TG): Patients will be treated conservatively and received sterile water via nasogastric tube After obtaining informed consent, the patient will be administered with either 100 mL of 350 mg Omnipaque or 100 mL of sterile water via nasogastric tube. The nasogastric tube will be clamped for 1 hour and patient will be positioned with 30 degree head elevation. In the contrast group (CG), surgery is indicated when contrast failed to reach the colon. Failure of conservative treatment is considered when there are no clinical improvements after 48 hours and the patient will then be proceeded for surgery.

Interventions

PROCEDURELow osmolar contrast

100 mL of 350 mg omnipaque will be administered via nasogastric tube

PROCEDURESterile water

100 mL of sterile water will be administered via nasogastric tube

Sponsors

Queen Savang Vadhana Memorial Hospital, Thailand
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Patients who are presented with clinical manifestation of small bowel obstruction due to adhesion and require radiological investigations * Patients who has history of abdominal surgery over 30 days

Exclusion criteria

* Patients with clinical signs and symptoms of bowel strangulation, ischemia, perforation or peritonitis * Patients with clinical signs and symptoms of bowel obstruction from non-adhesive causes, including malignancy, herniation, inflammatory bowel disease, Crohn's disease, and others. * Patients who has history of allergy to water soluble contrast agent

Design outcomes

Primary

MeasureTime frameDescription
Rate of operative interventionAt 72 hourPatients who developed signs of peritonitis or failed conservative treatment or no clinical improvement after 72 hours will be managed surgically

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026